Epigenomics AG

EANS-Voting Rights: Epigenomics AG
Release of a voting rights announcement according to article 26, section 1.1 WpHG (Securities Trading Act) with the aim of a Europe-wide distribution

--------------------------------------------------------------------------------
  Notification of voting rights transmitted by euro adhoc. The issuer is
  responsible for the content of this announcement.
-------------------------------------------------------------------------------- 
Person/company obliged to make the notification: 
----------------------------------- 
Name:    see notification
Place:   New York, NY
State:   USA 
Company data:
----------------------- 
Name:    Epigenomics AG
Address: Kleine Präsidentenstraße 1, 10178 Berlin
Place:   Berlin
State:   Deutschland 
Voting Rights: Release of a Voting Rights Notification Pursuant to § 26, para.
1 WpHG (German Securities Trading Act) with the Aim of an Europe-wide
Distribution 
Issuer: 
Epigenomics AG
Kleine Präsidentenstr. 1
10178 Berlin
Germany 
Voting Rights Notification: 
On 21 April 2010, Julian Baker, USA, notified Epigenomics AG of voting rights
in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22
para. 1 sent. 1 no. 1 WpHG and sec. 22 para. 2 WpHG as follows: 
On 19 April 2010, the share of Julian Baker in the voting rights of Epigenomics
AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as
at this date, to 5.12 per cent of the voting rights (i.e., 2,257,212 voting
rights of the 44,092,085 shares outstanding at that date) in Epigenomics AG. 
All 5.12 per cent of the voting rights (2,257,212 voting rights) are attributed
to Julian Baker pursuant to Sec. 22 para. 1 sent. 1 no. 1 WpHG through the
following entities controlled by Julian Baker: 
• Baker Brothers Life Sciences Capital (GP), LLC
                     • Baker Brothers Life Sciences Capital, L.P.
                     • Baker Brothers Life Sciences, L.P.

All 5.12 per cent of the voting rights (2,257,212  voting rights) of Baker 
Brothers Life Sciences, L.P. are additionally attributed to Julian Baker
pursuant to sec. 22 para. 2 WpHG. 
Furthermore, on 21 April 2010, Felix Baker, USA, notified Epigenomics AG of
voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection
with sec. 22 para. 1 sent. 1 no.1 WpHG and sec. 22 para. 2 WpHG as follows: 
On 19 April 2010, the share of Felix Baker in the voting rights of Epigenomics
AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as
at this date, to 5.12 per cent of the voting rights (2,257,212  voting rights)
in Epigenomics AG. 
All 5.12 per cent of the voting rights (2,257,212  voting rights) are
attributed to Felix Baker pursuant to sec. 22 para. 1 sent. 1 no.1 WpHG through
the following entities controlled by Felix Baker: 
• Baker Brothers Life Sciences Capital (GP),  LLC
                     • Baker Brothers Life Sciences Capital, L.P.
                     • Baker Brothers Life Sciences, L.P.

All 5.12 per cent of the voting rights (2,257,212  voting rights) of Baker 
Brothers Life Sciences, L.P. are additionally attributed to Felix Baker
pursuant to sec. 22 para. 2 WpHG. 
Furthermore, on 21 April 2010,  Baker Brothers Life Sciences Capital (GP),  LLC,
New York, NY, USA notified Epigenomics AG of voting  rights  in  Epigenomics  AG
pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1  no.
1 WpHG and sec. 22 para. 2 WpHG as follows: 
On 19 April 2010, the share of Baker Brothers Life Sciences  Capital  (GP),  LLC
in the voting rights of Epigenomics AG exceeded the  5  per  cent  threshold  of
sec. 21 para. 1 WpHG and amounted, as at this date, to  5.12  per  cent  of  the
voting rights (2,257,212) in Epigenomics AG. 
5.00 per cent of the voting rights (2,204,639 voting rights) are  attributed  to
Baker Brothers Life Sciences Capital (GP), LLC  pursuant  to  sec.  22  para.  1
sent. 1 no. 1 WpHG through the following entities controlled by  Baker  Brothers
Life Sciences Capital (GP), LLC: 
• Baker Brothers Life Sciences Capital, L.P.
                     • Baker Brothers Life Sciences, L.P.

0.12 per cent of the voting rights (52,573 voting rights) are attributed to 
Baker Brothers Life Sciences Capital (GP), LLC pursuant to sec. 22 para. 2
WpHG. 
Furthermore, on 21 April 2010, Baker Brothers Life Sciences Capital, L.P., New
York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG
pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no.
1 WpHG and sec. 22 para. 2 WpHG as follows: 
On 19 April 2010, the share of Baker Brothers Life Sciences Capital, L.P. in
the voting rights of Epigenomics AG exceeded the 5 per cent threshold of sec.
21 para. 1 WpHG and amounted, as at this date, to 5.12 per cent of the voting
rights (2,257,212) in Epigenomics AG. 
5.00 per cent of the voting rights (2,204,639 voting rights) are  attributed  to
Baker Brothers Life Sciences Capital, L.P. pursuant to sec. 22 para. 1  sent.  1
no. 1 WpHG through the  following  entity  controlled  by  Baker  Brothers  Life
Sciences Capital, L.P.: 
• Baker Brothers Life Sciences, L.P. 
0.12 per cent of the voting rights (52,573 voting rights) are attributed to
Baker Brothers Life Sciences Capital, L.P. pursuant to sec. 22 para. 2 WpHG. 
Furthermore, on 21 April 2010, Baker Brothers Life Sciences, L.P., New York,
NY, USA notified Epigenomics AG of voting rights in Epigenomics AG pursuant to
sec. 21 para. 1 WpHG in connection with sec. 22 para. 2 WpHG as follows: 
On 19 April 2010, the share of Baker Brothers Life Sciences, L.P. in the voting
rights of Epigenomics AG exceeded the 5 per cent threshold of sec. 21 para. 1
WpHG and amounted, as at this date, to 5.12 per cent of the voting rights
(2,257,212 voting rights) in Epigenomics AG. 
0.12 per cent of the voting rights (52,573 voting rights) are attributed to
Baker Brothers Life Sciences, L.P. pursuant to sec. 22 para. 2 WpHG. 
Furthermore, on 21 April 2010, 14159 Capital (GP), LLC, New York, NY, USA
notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21
para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 WpHG and sec. 22
para.2 WpHG as follows: 
On 19 April 2010, the share of  14159 Capital (GP), LLC in the voting rights of
Epigenomics AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and
amounted, as at this date, to 5.12 per cent of the voting rights (2,257,212
voting rights) in Epigenomics AG. 
0.12 per cent of the voting rights (52,573 voting rights) are attributed to
14159 Capital (GP), LLC pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG. 
5.00 per cent of the voting rights (2,204,639  voting rights) are attributed to
14159 Capital (GP), LLC pursuant to sec. 22 para. 2 WpHG through Baker Brothers
Life Sciences, L.P. 
Furthermore, on 21 April 2010, 14159 Capital, L.P., New York, NY, USA notified
Epigenomics AG of voting rights held in Epigenomics AG pursuant to sen. 21
para. 1 WpHG in connection with sen. 22 para. 1 sent. 1 no. 1 WpHG and sen. 22
para.2 WpHG as follows: 
On 19 April 2010, the share of 14159 Capital, L.P. in the voting rights of
Epigenomics AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and
amounted, as at this date, to 5.12 per cent of the voting rights (2,257,212
voting rights) in Epigenomics AG. 
0.12 per cent of the voting rights (52,573 voting rights) are attributed to
14159 Capital, L.P. pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG. 
5.00 per cent of the voting rights (2,204,639 voting rights) are attributed to
14159 Capital, L.P. pursuant to sec. 22 para. 2 WpHG through Baker Brothers
Life Sciences, L.P. 
Furthermore, on 21 April 2010, 14159, L.P., New York, NY, USA, notified
Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1
WpHG in connection with sec. 22 para.2 WpHG as follows: 
On 19 April 2010, the share of 14159, L.P. in the voting rights of Epigenomics
AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as
at this date, to 5.12 per cent of the voting rights (2,257,212 voting rights)
in Epigenomics AG. 
5.00 per cent of the voting rights (2,204,639 voting rights) are attributed to
14159, L.P. pursuant to Sec. 22 para. 2 WpHG through Baker Brothers Life
Sciences, L.P. 
Date of release: 22 April 2010 
Epigenomics AG
The Executive Board 
Contact: 
Epigenomics AG
Dr. Achim Plum
Senior Vice President Corporate Development
Tel.: +49 (0)30 24345 368
Fax: +49 (0)30 24345 555
Email: achim.plum@epigenomics.com 
end of announcement                               euro adhoc
-------------------------------------------------------------------------------- 

Further inquiry note:


Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade
Original-Content von: Epigenomics AG, übermittelt durch news aktuell

Themen in dieser Meldung


Das könnte Sie auch interessieren: